Shots:

• TeneoOne to receive $90M upfront and will take care of P-I trial for TNB-383B with its expected onset in H1’19. AbbVie to get exclusive WW rights to develop and commercialize Teneobio’s TNB-383B- with an option to acquire TeneoOne
• If AbbVie exercises option to acquire- TeneoOne will receive milestones on sales and regulatory approval of TNB-383B
• TNB-383B is a bispecific Ab used for targeting B-cell maturation antigen (BCMA) developed using TeneoOne’s anti-CD3 platform- will be evaluated in P-I for multiple myeloma

Ref: AbbVie | Image: AbbVie